Pharmaceutical raw materials are prepared by technologies of chemical synthesis, plant extracts or biotechnology. They are medicinal powder, crystallization, extract, etc. But the substances can not be taken directly by patients. These powders, crystalline, extracts are made to facilitate the patients. The dosage form is known as the drug formulation.
Division of pharmaceutical raw materials from the source can be divided into mineral resource, food resource, the former pharmaceutical raw materials such as chemical synthesis, such as traditional antibiotics, semi-synthetic penicillins, nutritional, and pharmaceutical excipients. Chinese pharmaceutical raw materials are mainly antibiotics, vitamins, steroid hormone, antipyretic analgesics, amino acids, and cardiovascular and cerebrovascular medication such as irinotecan price. In addition, now irinotecan is popular in international markets and irinotecan price is increasing higher.
Global Pharmaceutical market size in 2004 is about $ 68 billion. It is more than 90 billion U.S. dollars in 2008. Among them, generic pharmaceutical raw materials are growing rapidly. On the market in the world's bulk drugs, generic bulk drugs from $ 12 billion in 2004 to grow to $ 17 billion in 2008, average annual growth rate of 9.1%.
In 2008, global pharmaceutical raw materials retail market is mainly dominated by North America. Generic bulk drugs market is another situation, the Asia-Pacific region to lead the entire generic API market with 34.8 percent market share, while the North American market share is less than 25%. China has become the important role of the world's API market, the market share of 19.2 percent in 2008, while only 15.1% market share in 2004. In addition, after the United States the world's second largest generic raw material drug consuming countries.
China and India are the generic bulk drugs market grew the fastest of the two countries, the growth rate of 11.8% and 15.8%, respectively, these two countries account for about 1/4 share of the global generic bulk drugs market. Other developing countries, the rapid development in this area, including Latin America and Eastern Europe. The average annual growth rate is more than 9.4%.
However, people are not optimistic about the medical development of Western European countries. Compared to the United States, pharmaceutical industry in the regions is losing competitiveness. In addition, pharmaceutical raw materials market is more dynamic than the innovative pharmaceutical raw materials. The growth rate in this field of Western European countries is still low. It s is mainly because the government and pharmaceutical raw materials suppliers are failed to keep up with the pace in policy and hardware upgrading of market development. It is also coupled with expensive labor costs and shortage of competition sense. Pharmaceutical raw materials markets in Western Europe are gradually lost their former prestige.
Source:http://www.cospcn.com